Bellerophon will conduct $5.7 million at-the-market offering of stock

FBR Capital and MLV assist; to fund operations, corporate purposes

By Devika Patel

Knoxville, Tenn., May 27 – Bellerophon Therapeutics, Inc. negotiated a $5.7 million at-the-market equity offering with agents FBR Capital Markets & Co. and MLV & Co. LLC on May 27, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission.

The agents will be paid a 3% commission.

Proceeds will be used for operations and other general corporate purposes, including research and development, general working capital and possible acquisitions.

The clinical-stage therapeutics company is based in Hampton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.